Navigation Links
Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting

each drug to 26 different target receptor binding sites in the brain. Of the 26 potential target sites screened, dextromethorphan bound to the fewest suggesting a lower risk for side effects than the other drugs tested. The authors concluded that treatment effects with dextromethorphan in Involuntary Emotional Expression Disorder (IEED) may be related to the selectivity and affinity of dextromethorphan at Sigma1 receptor sites concentrated in the brainstem and cerebellum.

All three studies were sponsored by the Company.

About Zenvia

Zenvia is a combination of two well-characterized compounds, the therapeutically active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. The first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways, through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity, and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of Involuntary Emotional Expression Disorder (IEED) and diabetic peripheral neuropathic pain.

In October 2006, the Company received an approvable letter for the treatment of Zenvia in IEED. To address safety concerns raised in the FDA's approvable letter for Zenvia for the treatment of IEED, the company intends to initiate a confirmatory phase III study with a new lower quinidine dose formulation of Zenvia. In April 2007 Avanir completed the first of two planned phase III studies in diabetic peripheral neuropathic pain where all primary endpoints were successfully met. The Company is considering whether it would be necessary or advisable to study a similar lower dose of quinidine in the second phase III trial being planned for diabetic peripheral neuropathic pain.

About Avanir

Avanir Pharmaceuticals is focused on developing,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:2/8/2010)... 8 Cost reductions offset a recession-driven ... AHPI ) narrowly back into profitability in the second ... quarter ended December 31, 2009 declined almost ... the same quarter last year to $11.4 million ... sales were reduced even more sharply, from approximately ...
(Date:2/8/2010)... N.J. , Feb. 8 Savient ... the company will release financial results for the fourth ... market on Thursday, February 25, 2010 . ... Group Vice President and Chief Financial Officer, will host ... a.m. Eastern Time on February 26, 2010 ...
(Date:2/8/2010)... BETHESDA, Md. , Feb. 8 Hanger ... that it plans to report its results of operations for ... Wednesday, February 10, 2010 . ,, The Company plans to ... ended December 31, 2009 on Wednesday, February ... conference call is scheduled to begin at 9:00 a.m., ...
Breaking Medicine Technology:Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2Diabetes cases to double and costs to triple by 2034 62179 1Diabetes cases to double and costs to triple by 2034 62179 2Diabetes cases to double and costs to triple by 2034 62179 3Nanowires key to future transistors electronics 14983 1Nanowires key to future transistors electronics 14983 2Nanowires key to future transistors electronics 14983 3Research sheds light on workings of anti cancer drug 62178 1Research sheds light on workings of anti cancer drug 62178 2Research sheds light on workings of anti cancer drug 62178 3
(Date:2/9/2010)... found larger, for-profit hospitals more likely to insert them ... and those that are set up to make a ... patients with advanced dementia, despite evidence that the practice ... and other problems. , "Our results suggest that decisions ... go to than a decision-making process that really elicits ...
(Date:2/9/2010)... Warns Against Insurer-favored ,Cost Solution,: Selling Policies That Amount ... ,, WASHINGTON , Feb. 9 /PRNewswire-USNewswire/ ... and regulators with its premium hikes of up to ... the face of questions from the White House and ... and state lawmakers should act to regulate health insurance ...
(Date:2/9/2010)... , Feb. 9 In conjunction with ... Laser Spine Institute (LSI) sponsored the first-annual Gridiron Greats ... Assistance Fund hosted by Mike Ditka and ... players and coaches, Gridiron Greats is a non-profit organization that ... in crisis. ,, This year, Gridiron Greats recognized LSI ...
(Date:2/9/2010)... are bred in captivity primarily for their skins, but ... their meat. A study shows that eating these animals ... wisdom of eating this ,delicacy., , Parasites, bacteria and ... metals and residues of veterinary drugs- eating reptile meat ... conclusion of a study published in the International ...
(Date:2/9/2010)... Health Freedom Act Could See Idaho Lose $1.6 Billion ... BOISE, Idaho , Feb. 9 As ... oppose a non-existent federal health care law, the long-term effects ...  AARP is calling the Idaho Health Freedom Act (House Bill ... signed into law, could see Idaho lose nearly ...
Breaking Medicine News(10 mins):Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2Health News:Study carried out into biological risks of eating reptiles 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4
... ORLEANS, May 6 Litigation surrounding health and damage ... June 18 conference to be held in New Orleans. ... law firm Baron & Budd, according to HB Litigation ... teleconferences on the subject, one for insurance attorneys and ...
... three genetic ties to brain metastasis, , , WEDNESDAY, May 6 ... breast cancer to the brain have been identified by U.S. ... treatments. , The spread, or metastasis, of breast cancer to ... been removed. Experts say this suggests that the cancer cells ...
... 6 Two scientists whose work has led to ... muscular dystrophy have been chosen to receive the 2009 ... Ph.D. and Louis M. Kunkel, Ph.D., share the 2009 ... the genes and proteins that cause muscular dystrophy, a ...
... May 6 The National Hospice and Palliative Care ... of Health and Human Services. Her Senate confirmation ... day in office, was the final appointment to President,s ... at the helm of HHS at a time when ...
... Former McKesson executive to lead further innovation of ... government agencies and wellness companiesBEDFORD, Mass., May 6 ... management software solutions, today announced that Bill Wisotzkey ... and design, effective immediately. Wisotzkey has more than ...
... $1.5 Million - $3 MillionPRINCETON, N.J., May 6 ... DSCI), a manufacturer and marketer of advanced wound care products, ... private label adhesive bandages to one of the largest medical ... are expected to range between $1.5 to $3.0 million for ...
Other Medicine News:Health News:HB Litigation Conferences Announces Conference and Two Teleconferences on Chinese Drywall Litigation and Insurance 2Health News:Genes Linked to Spread of Breast Cancer 2Health News:March of Dimes Awards $250,000 Prize to Scientists Unraveling the Causes of Muscular Dystrophy 2Health News:NHPCO Welcomes Kathleen Sebelius as HHS Secretary 2Health News:Casenet Names Bill Wisotzkey Vice President of Product Management and Design 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 3
... innovative design, the Burton 7500-I refractor delivers ... At Burton, we set out not only ... innovative concept, but to set the industry ... and stringent testing, we devote more resources ...
... The Company has developed the patented ... the LASIK procedure. Management and industry experts ... keratotomy instrument, or microkeratome, currently used in ... cadaver eye studies, the Company has demonstrated ...
3.5v Ophthalmic Diagnostic Set with AutoStep Coaxial Ophthalmoscope, Spot Retinoscope, Rechargeable Handle, and Soft Case. High-quality eyecare from the preferred name in diagnostic instruments....
3.5v Ophthalmic Diagnostic Set with Diagnostic Ophthalmoscope, Spot Retinoscope, Rechargeable Handle, and Soft Case. High-quality eyecare from the preferred name in diagnostic instruments....
Medicine Products: